Highlights

  • ResMed Inc (ASX:RMD) was trading at AUD 31.18, down 1.42% at the time of writing on 18 August 2026.
  • The company released Q4 FY26 results on 6 August 2026, reporting quarterly Revenue of US$1.464 billion, up 9% year on year.
  • ResMed reported FY26 revenue of US$5.7 billion, up 10% year on year, with FY26 free Cash Flow of US$1.6 billion.
  • The S&P/ASX 200 Health Care (ASX:XHJ) was trading at 30,834.80 points, up 7.92% (+2,262.60) today.

ResMed Inc (ASX:RMD) was trading at AUD 31.18, down 1.42% at the time of writing on 18 August 2026. The company’s share price movement comes as investors continue to assess its latest financial performance, sleep health technology portfolio and broader healthcare market position.

The broader Australian market was trading in positive territory, with the S&P/ASX 200 (ASX:XJO) at 9,085.20 points, up 0.13% (+12.00) today. The S&P/ASX 300 (ASX:XKO) was trading at 9,022.40 points, up 0.16% (+14.20) today. Within healthcare, the S&P/ASX 200 Health Care (ASX:XHJ) was trading at 30,834.80 points, up 7.92% (+2,262.60) today.

Daily share price movements can reflect investor sentiment, sector trends, market expectations and trading activity. However, a single Trading session does not necessarily indicate a change in a company’s fundamentals, financial performance or long-term outlook.

Investors generally monitor medical technology companies through revenue growth, product demand, innovation programs, regulatory developments, market expansion and financial management.

Sleep health and respiratory care business

ResMed is a global medical technology company focused on sleep health, respiratory care and digital health solutions. The company develops devices, masks, software platforms and connected healthcare solutions used in the diagnosis and treatment of sleep apnea and other respiratory conditions.

Its product portfolio includes positive airway pressure devices, masks, ventilation systems and cloud-based healthcare software. ResMed serves healthcare providers, patients and medical networks across multiple international markets.

The company’s Business model combines medical device Manufacturing with digital health capabilities. Its connected platforms allow healthcare providers to monitor therapy progress and support patient management.

ResMed operates in markets influenced by healthcare access, diagnosis rates, ageing populations and Demand for home-based treatment options. Medical technology companies are generally assessed through product adoption, innovation capability, manufacturing execution and regulatory compliance.

Latest Q4 FY26 update and financial performance

ResMed released its Q4 FY26 results on 7 August 2026, covering the three months ended 30 June 2026. The company reported quarterly revenue of US$1.464 billion, up 9% year on year and up 8% on a constant currency basis.

During Q4 FY26, Sleep and Breathing Health revenue increased 9% year on year. Americas Sleep and Breathing Health revenue increased 8%, Rest of World Sleep and Breathing Health revenue increased 10% on a constant currency basis, while Residential Care Software revenue increased 2% on a constant currency basis.

ResMed reported Q4 FY26 GAAP Diluted Earnings per Share of US$2.64, up 2% year on year, while non-GAAP diluted earnings per share increased 16% to US$2.95. The company reported GAAP gross Margin of 58.8% during the quarter.

The company also reported Q4 FY26 Operating Cash Flow of US$455 million and free cash flow of US$404 million.

For the full FY26 period, ResMed reported revenue of US$5.7 billion, up 10% year on year. FY26 GAAP gross margin increased to 61.1%, GAAP Operating Margin was 33.4%, and non-GAAP operating margin was 36.1%. FY26 non-GAAP diluted earnings per share was US$11.17, up 17% year on year.

ResMed generated FY26 operating cash flow of US$1.8 billion and free cash flow of US$1.6 billion. During FY26, the company returned US$1.0 billion to shareholders through share repurchases and dividends.

Product innovation and digital healthcare strategy

Product innovation remains a key component of ResMed’s strategy. The company continues to develop sleep and respiratory care products while expanding digital health capabilities.

During FY26, ResMed completed the Acquisition of Noctrix Health, a medical device company focused on wearable therapeutics for Restless Leg Syndrome. The company also entered a Partnership with ŌURA to expand access to sleep health education and care pathways.

ResMed continued product launches across international markets during FY26, including AirSense 11 in Taiwan, AirCurve 11 ST/ST-A in the United States and AirTouch F30i Comfort in Brazil and Chile.

The company’s combination of devices and software platforms reflects the broader shift towards connected healthcare models. Investors generally monitor adoption rates, software engagement and the ability of digital tools to support patient outcomes and healthcare efficiency.

The company’s agreement to sell the MatrixCare business is also part of its Portfolio Management approach. The transaction is expected to close during FY27, subject to completion conditions.

Factors investors monitor for ResMed

Medical technology companies operate within regulated healthcare markets where product approvals, reimbursement conditions and healthcare spending patterns can influence performance.

For ResMed, investors generally monitor demand for sleep devices, masks and accessories, as well as growth across digital health platforms.

The sleep apnea market remains an important area of focus, with diagnosis rates, treatment adoption and healthcare accessibility influencing long-term demand. Product innovation and software integration are also monitored as healthcare systems increasingly adopt connected solutions.

Global operations create exposure to currency movements, regional healthcare policies and market conditions across different geographies.

Competition within respiratory care and sleep technology markets is another consideration. Companies operating in this space generally require ongoing Research and Development Investment to maintain product relevance.

Financial discipline also remains an area of investor focus, including cash generation, Capital allocation, acquisitions and Shareholder returns.

A daily share price decline does not independently confirm weaker company fundamentals. Investors generally review financial results, operational performance, product developments and healthcare sector conditions when assessing medical technology businesses.

Healthcare technology outlook and future considerations

The healthcare technology sector continues to evolve through increased adoption of digital solutions, home-based care models and connected medical devices.

For ResMed, future investor attention is likely to remain on sleep and breathing health demand, product launches, digital healthcare adoption, operational efficiency and global market performance.

The company’s share price was trading at AUD 31.18, down 1.42% at the time of writing on 18 August 2026. While daily movements reflect short-term market activity, broader company assessment generally involves reviewing financial performance, product portfolio development and long-term healthcare trends.

Conclusion

ResMed (ASX:RMD) continues to operate as a global medical technology company focused on sleep health, respiratory care and digital healthcare solutions. The company’s share price was trading at AUD 31.18, down 1.42% at the time of writing on 18 August 2026. Q4 FY26 results highlighted continued revenue growth, while FY26 results reflected higher revenue, operating margins and cash generation. Investors generally continue to monitor product demand, digital health expansion and healthcare technology trends.